HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NanoBio Nasal Antiseptic, Burst Oral-Care Probiotics And More: Personal Care Launch News

Executive Summary

Recent personal-care product launches show companies innovating in emerging frontiers and hazily regulated territory with probiotic oral care, over-the-counter fungal nail care and nasal antiseptic care. Elsewhere, sensitive skin specialist Cetaphil introduces ultra-moisturizing products, and Nestle Health Sciences’ Atrium Innovations launches a line of nutritional supplements for skin, hair and nail health.

You may also be interested in...



NAD Case Reopened, But Fungi-Nail Marketer Fails Again With ‘#1 Pharmacist Recommended’ Claim

New Jersey-based Arcadia Consumer Healthcare, Inc., succeeded in reopening a 2018 National Advertising Division case involving its ‘#1 Pharmacist Recommended’ claim for the Fungi-Nail line, but failed again to convince the NAD that survey findings justify the claim.

Vital Proteins’ ‘Timely’ Immunity Product Launch Makes Time Right For Nestle Investment

Nestle Health Science has majority stake in US firm that started offering a powder blend for beverages containing vitamin C, collagen, L glutamine, zinc, electrolytes and beta glucan earlier in 2020, when consumer interest spiked in boosting immunity health.

Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

Related Content

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel